ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January

BREAKING: S&P 500 Closes Just Below Key Level In Divergent Week

ARS Pharmaceuticals (SPRY) stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary ahead of a July 1 deadline. The decision came as a "negative shock given management's prior guidance towards reaching a potential agreement in time and updates suggesting positive progress on the contract," William Blair analyst Lachlan Hanbury-Brown said in a note…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

6/22/2026 Alissa Coram and Justin Nielsen walk through Monday's market action and discuss key stocks to watch in Stock Market Today.

6/22/2026 Alissa Coram and Justin Nielsen walk through Monday's market action...

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!

Get market updates, educational videos, webinars, and stock analysis.

Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.

Fuente original: Yahoo Finance (https://www.investors.com/news/technology/ars-pharmaceuticals-stock-cvs-caremark-neffy-coverage/?src=A00220&yptr=yahoo)